Oncology and Hematology

273-288 of 595

Reducing Prostate Cancer Cell Production: The Role of Bipolar Androgen Therapy
Reducing Prostate Cancer Cell Production: The Role of Bipolar Androgen Therapy
On the Frontlines of Prostate Cancer
Reducing Prostate Cancer Cell Production: The Role of Bipolar Androgen Therapy
- Mohit Khera, M.D., M.B.A., M.P.H.
MinuteCE®
Chemotherapy Strategies in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
0.25 credits 2 episodes
- Eileen O’Reilly, MD
- Efrat Dotan, MD
0.25 credits 2 episodes
HER2 Testing: The Evolving Role of Immunohistochemistry (IHC)
HER2 Testing: The Evolving Role of Immunohistochemistry (IHC)
CME/CE
HER2 Testing: The Evolving Role of Immunohistochemistry (IHC)
- Fernando López-Ríos, MD, PhD
- Christian Rolfo, MD, PhD
- Charlie Gourley, MD, PhD
Reducing Patient Time Burden in HER2+ Breast Cancer with Subcutaneous Trastuzumab/Pertuzumab
Reducing Patient Time Burden in HER2+ Breast Cancer with Subcutaneous Trastuzumab/Pertuzumab
Project Oncology®
Reducing Patient Time Burden in HER2+ Breast Cancer with Subcutaneous Trastuzumab/Pertuzumab
Prostate Cancer Care: Testosterone Therapy’s Impact on Biochemical Recurrence
Prostate Cancer Care: Testosterone Therapy’s Impact on Biochemical Recurrence
On the Frontlines of Prostate Cancer
Prostate Cancer Care: Testosterone Therapy’s Impact on Biochemical Recurrence
- Mohit Khera, M.D., M.B.A., M.P.H.
Reevaluating Testosterone: A Paradigm Shift in Prostate Cancer Treatment
Reevaluating Testosterone: A Paradigm Shift in Prostate Cancer Treatment
On the Frontlines of Prostate Cancer
Reevaluating Testosterone: A Paradigm Shift in Prostate Cancer Treatment
- Mohit Khera, M.D., M.B.A., M.P.H.
Examining the Role of Bacterial Biofilms in Colorectal Cancer Screening
Examining the Role of Bacterial Biofilms in Colorectal Cancer Screening
Clinician's Roundtable
Examining the Role of Bacterial Biofilms in Colorectal Cancer Screening
Slowing Prostate Cancer Progression: The Role of Dietary Fat Modifications
Slowing Prostate Cancer Progression: The Role of Dietary Fat Modifications
On the Frontlines of Prostate Cancer
Slowing Prostate Cancer Progression: The Role of Dietary Fat Modifications
- William Aronson, MD
Early-Stage Prostate Cancer Treatment: Examining Long-Term Complications
Early-Stage Prostate Cancer Treatment: Examining Long-Term Complications
On the Frontlines of Prostate Cancer
Early-Stage Prostate Cancer Treatment: Examining Long-Term Complications
- Joseph Unger, PhD, MS
Advancing Cancer Care: Key Considerations for Subcutaneous Immunotherapies
Advancing Cancer Care: Key Considerations for Subcutaneous Immunotherapies
Project Oncology®
Advancing Cancer Care: Key Considerations for Subcutaneous Immunotherapies
- Charles Turck, PharmD, BCPS, BCCCP
- Matthew Hadfield, MD
From Diagnosis to Treatment: Challenges in Glioblastoma Care
From Diagnosis to Treatment: Challenges in Glioblastoma Care
NeuroFrontiers
From Diagnosis to Treatment: Challenges in Glioblastoma Care
- Lauren Schaff, MD
MinuteCE®
Mastering Mutation-Driven mCRC: From Testing to Targeted Therapy
1.00 credit 10 episodes
- Jenny Seligmann, MBChB, PhD
- Fortunato Ciardiello, MD, PhD
- Scott Kopetz, MD, PhD
- Cathy Eng, MD, FACP
1.00 credit 10 episodes
Mutational Testing in mCRC: Methods and Data Driving Treatment Selection
Mutational Testing in mCRC: Methods and Data Driving Treatment Selection
MinuteCE®
Mutational Testing in mCRC: Methods and Data Driving Treatment Selection
1.00 program credit
- Fortunato Ciardiello, MD, PhD
- Jenny Seligmann, MBChB, PhD
1.00 program credit
From Guidelines to Practice: First-Line Treatment Choices in mCRC
From Guidelines to Practice: First-Line Treatment Choices in mCRC
MinuteCE®
From Guidelines to Practice: First-Line Treatment Choices in mCRC
1.00 program credit
- Fortunato Ciardiello, MD, PhD
- Jenny Seligmann, MBChB, PhD
1.00 program credit
Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond
Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond
MinuteCE®
Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond
1.00 program credit
- Fortunato Ciardiello, MD, PhD
- Jenny Seligmann, MBChB, PhD
1.00 program credit
Proactive Adverse Effect Management in mCRC: Improving Tolerability to Optimize Patient Outcomes
Proactive Adverse Effect Management in mCRC: Improving Tolerability to Optimize Patient Outcomes
MinuteCE®
Proactive Adverse Effect Management in mCRC: Improving Tolerability to Optimize Patient Outcomes
1.00 program credit
- Fortunato Ciardiello, MD, PhD
- Jenny Seligmann, MBChB, PhD
1.00 program credit